Edition:
United Kingdom

ARCA Biopharma Inc (ABIO.OQ)

ABIO.OQ on NASDAQ Stock Exchange Capital Market

5.64USD
16 Aug 2019
Change (% chg)

$0.07 (+1.26%)
Prev Close
$5.57
Open
$5.59
Day's High
$6.28
Day's Low
$5.47
Volume
44,299
Avg. Vol
150,460
52-wk High
$20.40
52-wk Low
$4.72

Latest Key Developments (Source: Significant Developments)

Arca Biopharma Posts Q2 Loss Per Share Of $1.14
Thursday, 1 Aug 2019 

Aug 1 (Reuters) - ARCA Biopharma Inc ::ARCA BIOPHARMA ANNOUNCES SECOND QUARTER 2019 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE.Q2 LOSS PER SHARE $1.14.PRECISION-AF CLINICAL TRIAL INITIATION ANTICIPATED IN Q1 OF 2020.CASH AND CASH EQUIVALENTS WERE $9.97 MILLION AS OF JUNE 30, 2019, COMPARED TO $6.6 MILLION AS OF DECEMBER 31, 2018.ARCA BIOPHARMA - WILL NEED TO RAISE ADDITIONAL CAPITAL, AND/OR COMPLETE PARTNERSHIP OR OTHER POSSIBLE STRATEGIC TRANSACTION, TO FUND FUTURE OPERATIONS.ARCA - WILL NEED TO RAISE ADDITIONAL CAPITAL, COMPLETE PARTNERSHIP OR OTHER POSSIBLE STRATEGIC TRANSACTION, TO DEVELOP GENCARO OR ANY OTHER PRODUCT CANDIDATES.  Full Article

Arca Biopharma Says Cash As Of March 31 To Be Sufficient To Fund Operations Through Q1 2020
Friday, 28 Jun 2019 

June 28 (Reuters) - ARCA Biopharma Inc ::ARCA BIOPHARMA SAYS ENTERED INTO AMENDMENT NO. 6 TO ITS CAPITAL ON DEMAND(TM)SALES AGREEMENT, DATED AS OF JANUARY 11, 2017 - SEC FILING.ARCA BIOPHARMA - AMENDMENT INCREASED MAXIMUM OFFERING VALUE OF SHARES OF CO'S STOCK WHICH CO MAY ISSUE, SELL UNDER AMENDED SALES AGREEMENT TO $17.5 MILLION.ARCA BIOPHARMA - BELIEVES CASH & CASH EQUIVALENTS AS OF MARCH 31, 2019 TO BE SUFFICIENT TO FUND OPERATIONS, AT CURRENT COST STRUCTURE, THROUGH Q1 2020.  Full Article

ARCA Biopharma Says Co Entered Into Amendment No. 5 To Its Capital On Demand(Tm)Sales Agreement, Dated As Of January 11, 2017
Monday, 20 May 2019 

May 20 (Reuters) - ARCA Biopharma Inc ::ARCA BIOPHARMA INC - ENTERED INTO AMENDMENT NO. 5 TO ITS CAPITAL ON DEMAND(TM)SALES AGREEMENT, DATED AS OF JANUARY 11, 2017.ARCA BIOPHARMA - AMENDMENT INCREASED MAXIMUM AGGREGATE OFFERING VALUE OF SHARES OF STOCK WHICH COMAY ISSUE AND SELL BY $1 MILLION TO $16.8 MILLION.ARCA BIOPHARMA - BELIEVES ITS CASH AND CASH EQUIVALENTS WILL BE SUFFICIENT TO FUND ITS OPERATIONS THROUGH FISCAL YEAR ENDING DEC 31, 2019..  Full Article

Arca Biopharma Says Filed Amendment To Implement Reverse Split Of Common Stock
Wednesday, 3 Apr 2019 

April 3 (Reuters) - ARCA Biopharma Inc ::ARCA BIOPHARMA INC - FILED AMENDMENT TO IMPLEMENT AN EIGHTEEN-FOR-ONE REVERSE SPLIT OF ITS COMMON STOCK AS PREVIOUSLY AUTHORIZED.ARCA BIOPHARMA INC - REVERSE SPLIT WILL BE EFFECTIVE AS OF 5:01 P.M. EASTERN TIME ON APRIL 3.  Full Article

Arca Biopharma Has Cash And Cash Equivalents Totaling $6.6 Mln (Unaudited) As Of Dec. 31
Wednesday, 20 Feb 2019 

Feb 20 (Reuters) - ARCA Biopharma Inc ::ARCA BIOPHARMA INC - AS OF DECEMBER 31, 2018, HAD CASH AND CASH EQUIVALENTS TOTALING $6.6 MILLION (UNAUDITED).ARCA BIOPHARMA INC - BELIEVES THAT FUNDS WILL BE SUFFICIENT TO FUND ITS OPERATIONS, AT ITS PROJECTED COST STRUCTURE, THROUGH END OF Q2 OF 2019..  Full Article

Arca Biopharma Inc - Gencaro Development Program Has FDA Fast Track Designation
Wednesday, 20 Feb 2019 

Feb 20 (Reuters) - ARCA Biopharma Inc ::ARCA BIOPHARMA ANNOUNCES FDA AGREEMENT FOR A SINGLE PHASE 3 CLINICAL TRIAL TO SUPPORT APPROVAL FOR THE FIRST GENETICALLY-TARGETED CARDIOVASCULAR DRUG.ARCA BIOPHARMA INC - 58% TREATMENT BENEFIT SEEN VERSUS ACTIVE COMPARATOR IN PHASE 2B FOR PLANNED PHASE 3 TARGET POPULATION.ARCA BIOPHARMA INC - GENCARO DEVELOPMENT PROGRAM HAS FDA FAST TRACK DESIGNATION.ARCA BIOPHARMA INC - U.S. AND EUROPEAN CARDIOVASCULAR PATENTS AND REGULATIONS MAY PROVIDE COMMERCIAL EXCLUSIVITY FOR GENCARO FOR 10 YEARS POST APPROVAL.  Full Article

Arca Biopharma Updates Special Protocol Assessment Request To FDA
Thursday, 20 Dec 2018 

Dec 20 (Reuters) - ARCA Biopharma Inc ::ARCA BIOPHARMA UPDATES SPECIAL PROTOCOL ASSESSMENT REQUEST TO FDA FOR GENCARO PHASE 3 ATRIAL FIBRILLATION CLINICAL TRIAL.ARCA BIOPHARMA INC - PHASE 3 ATRIAL FIBRILLATION TRIAL PLANNED IN POPULATION WITH NO EFFECTIVE OR FDA APPROVED THERAPIES.ARCA BIOPHARMA INC - PHASE 3 ATRIAL FIBRILLATION TRIAL PLANNED IN POPULATION WITH NO EFFECTIVE OR FDA APPROVED THERAPIES.ARCA BIOPHARMA INC - ARCA ANTICIPATES INITIATING PRECISION-AF IN SECOND HALF OF 2019.  Full Article

Arca Biopharma Announces Positive Outcome Of End-Of-Phase 2 Meeting With FDA On Gencaro Development For Atrial Fibrillation
Tuesday, 31 Jul 2018 

July 31 (Reuters) - ARCA Biopharma Inc ::ARCA BIOPHARMA ANNOUNCES POSITIVE OUTCOME OF END-OF-PHASE 2 MEETING WITH FDA ON GENCARO DEVELOPMENT FOR ATRIAL FIBRILLATION.ARCA BIOPHARMA INC - SINGLE PHASE 3 TRIAL MAY BE SUFFICIENT FOR APPROVAL OF ATRIAL FIBRILLATION INDICATION.ARCA BIOPHARMA INC - PHASE 3 CLINICAL TRIAL SPECIAL PROTOCOL ASSESSMENT SUBMISSION ANTICIPATED 3Q2018.ARCA BIOPHARMA - FDA SUGGESTED CO SUBMIT SPA APPLICATION, WHICH CO ANTICIPATES SUBMITTING IN Q3 2018.ARCA - EXPECTS INITIATING PHASE 3 CLINICAL TRIAL SUBJECT TO SECURING MORE FINANCING BY STRATEGIC PARTNERSHIP AND/OR ADDITIONAL SALES OF SECURITIES.  Full Article

Arca Biopharma Q1 Loss Per Share $0.20
Tuesday, 8 May 2018 

May 8 (Reuters) - ARCA Biopharma Inc ::ARCA BIOPHARMA ANNOUNCES FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE.Q1 LOSS PER SHARE $0.20.  Full Article

Arca Biopharma announces issuance of European patent on cardiovascular disease treatment methods
Thursday, 16 Nov 2017 

Nov 16 (Reuters) - Arca Biopharma Inc :Arca Biopharma announces issuance of European patent for treating cardiovascular diseases and conditions with a new chemical entity utilizing genetic targeting.Arca Biopharma- believes current cash, cash equivalents,marketable securities will be sufficient to fund its operations through end of Q2 of 2018​.  Full Article